Document:

Seventh Amendment to Securities Purchase Agreement

 Exhibit 10.10 
 SEVENTH AMENDMENT AGREEMENT 
 This SEVENTH AMENDMENT AGREEMENT (this
“Seventh Amendment”) is made and entered into as of April 25, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation, “Galena”) and
RXi Pharmaceuticals Corporation (formerly RNCS, Inc., “RXi”). 
 WHEREAS, the parties entered into a Securities
Purchase Agreement dated as of September 24, 2011 (the “Securities Purchase Agreement”) and the Ancillary Agreements related thereto, including the Bridge Notes; 

WHEREAS, the parties entered into several Omnibus Amendments dated as of February 6, 2012, March 5,
2012, March 30, 2012, April 3, 2012, April 11, 2012 and April 18, 2012 (the “Previous Amendments”), amending certain provisions of the Securities Purchase Agreement and the Bridge Notes;

 WHEREAS, in light of certain developments with respect to litigation to which Galena is a party, RXi and the Investors wish
to be indemnified and held harmless against any losses arising out of such litigation, and Galena wishes to so indemnify RXi and the Investors; 
 WHEREAS, Galena wishes to be assured, prior to effecting the Spin-Off, that certain facts of which the Investors are presently aware would not constitute a failure of a condition to the obligations of the
Investors at the Closing; 
 WHEREAS, the parties desire to amend or waive certain other provisions of the Securities Purchase
Agreement; 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1. Certain
Definitions. References herein to the “Securities Purchase Agreement” mean the Securities Purchase Agreement as amended by the Previous Amendments and by this Amendment, as the context requires. Capitalized terms used but not defined
herein have the meanings ascribed in the Securities Purchase Agreement. 
 2. Indemnification of RXi and the Investors.
Galena hereby agrees that, subject to the Closing, Galena’s indemnification obligations under Section 9.01 of the Securities Purchase Agreement shall apply to all losses, liabilities, deficiencies, costs, damages and expenses (including,
without limitation, reasonable attorneys’ fees, charges and disbursements) incurred after the Closing as a result of as a result of claims brought by any of Galena’s warrant holders solely arising out of or relating to the transactions
contemplated by the Securities Purchase Agreement. Galena further agrees to indemnify RXi to the same extent it agrees to indemnify the Investors pursuant to the foregoing sentence. Galena’s obligations under this Section 2 are subject to
all of the provisions of Article IX of the Securities Purchase Agreement. 
 3. Certain Assurances. Each of the Investors
hereby agrees and represents that, based on the information available to it, the execution and delivery of the Separation and 

 
Settlement Agreement, dated as of the Closing Date, among RXi, Galena, the Investors, Anastasia Khvorova, Ph.D. and Advirna, LLC resolves and satisfies any and all conditions to the Closing
contained in Article V of the Agreement as they relate to the employment of Dr. Khvorova by RXi or Galena or RXi’s or Galena’s prior dealings with Advirna, LLC. Each of the Investors and the other parties further agrees and represents
that the provisions of Section 4.12(a) and Section 4.13(b) solely with respect to the time limits contained therein are hereby waived by all the parties. 
 4. Miscellaneous. Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement as amended. The terms and conditions set forth in Article X of
the Securities Purchase Agreement are incorporated herein by reference. Except as specifically set forth in Section 3 hereof, nothing herein shall constitute a waiver of any provision of the Securities Purchase Agreement or any of the Ancillary
Documents pursuant to Section 10.03 of the Securities Purchase Agreement. 
 [Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have executed this Seventh Amendment as of the date
first above written. 
  

			
	GALENA BIOPHARMA, INC.
		
	By:	 	/s/ Mark J. Ahn
		 	 Name: Mark J. Ahn

Title:   President and Chief Executive

            Officer

  

			
	RXi PHARMACEUTICALS CORPORATION
		
	By:	 	/s/ Mark J. Ahn
		 	 Name: Mark J. Ahn

Title:   President

  

			
	TANG CAPITAL PARTNERS, LP
		
	By:	 	/s/ Kevin C. Tang
		 	 Name: Kevin C. Tang

Title:   Managing Director

  

			
	RTW INVESTMENTS, LLC
		
	By:	 	/s/ Roderick Wong
		 	 Name: Roderick Wong

Title:  Managing Member

 [Signature Page to Seventh Omnibus Agreement] 

  
 3First Amendment to Agreement to License by and between NAI andCompound Solutions

 Exhibit 10.33 
 FIRST AMENDMENT TO 
 AGREEMENT TO LICENSE 

This First Amendment (“Amendment”) to the Agreement to License by and between Natural Alternatives
International, Inc., a Delaware corporation (“NAI”), and Compound Solutions, Inc., a California corporation (“CSI”), dated effective as of July 1, 2011 (“Agreement”), is made and entered into effective as of
January 6, 2012 (“Effective Date”). Unless otherwise defined herein, capitalized terms shall have the meanings given them in the Agreement. 
 1. The License Agreement attached to the Agreement as Exhibit B is hereby replaced in its entirety with the License Agreement attached hereto. 

2. Except as set forth herein, all other terms and conditions of the Agreement shall remain in full force and effect.

 3. This Amendment may be executed in any number of counterparts, each of which when so executed and delivered
shall be deemed an original, and such counterparts together shall constitute one instrument. Delivery by facsimile or other electronic means of an executed counterpart hereof shall have the same force and effect as delivery of an originally executed
counterpart hereof. 
 [Signatures on following page.] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the
Effective Date. 
  

	
	NAI
	
	Natural Alternatives International, Inc.,
a Delaware corporation
	
	 /s/ Mark A. LeDoux

	Mark A. LeDoux, Chief Executive Officer
	
	CSI
	
	Compound Solutions, Inc.,
a California corporation
	
	 /s/ Matt Titlow

	Matt Titlow, Chief Executive OfficerSecondAmendment to Agreement toLicense by and between NAI and Compound Solutions

 Exhibit 10.34 
 SECOND AMENDMENT TO 
 AGREEMENT TO LICENSE 

This Second Amendment (“Amendment”) to the Agreement to License by and between Natural Alternatives
International, Inc., a Delaware corporation (“NAI”), and Compound Solutions, Inc., a California corporation (“CSI”), dated effective as of July 1, 2011, as amend by that certain First Amendment to Agreement to License
effective as of January 6, 2012 (“Agreement”), is made and entered into effective as of March 19, 2012 (“Effective Date”). Unless otherwise defined herein, capitalized terms shall have the meanings given them in the
Agreement. 
 1. The term “CSI,” as used in the Agreement, including in each amendment to the
Agreement, is revised to refer to Compound Solutions, Inc., together with its successors, transferees and assigns. 
 2. Schedule 1 to the Agreement is hereby replaced in its entirety with the Schedule 1 attached hereto. 
 3. Except as set forth herein, all other terms and conditions of the Agreement shall remain in full force and effect. 

4. This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be
deemed an original, and such counterparts together shall constitute one instrument. Delivery by facsimile or other electronic means of an executed counterpart hereof shall have the same force and effect as delivery of an originally executed
counterpart hereof. 
 [Signatures on following page.] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the
Effective Date. 
  

	
	NAI
	
	Natural Alternatives International, Inc.,
a Delaware corporation
	
	 /s/ Kenneth E. Wolf

	Kenneth E. Wolf, Chief Operating Officer & Chief Financial Officer
	
	CSI
	
	Compound Solutions, Inc.,
a California corporation
	
	 /Matthew Titlow

	Matthew Titlow, Chief Executive OfficerFirst Amendment to Manufacturing Agreement by and between NSA, Inc. and NAI

 Exhibit 10.35 
 FIRST AMENDMENT TO 
 MANUFACTURING AGREEMENT 

This First Amendment (“Amendment”) to the Manufacturing Agreement by and between Natural Alternatives
International, Inc., a Delaware corporation (“Seller”), and NSA, Inc., a Tennessee corporation (“NSA”), dated as of April 1, 2005 (“Agreement”), is made and entered into effective as of April 1, 2012
(“Effective Date”). Unless otherwise defined herein, capitalized terms shall have the meanings given them in the Agreement. 
 1. Section 12 of the Agreement is hereby replaced in its entirety with the following: 
 12. Term. Subject to Section 14 of this Agreement, the term of this Agreement shall commence on the date first written hereinabove and shall expire at the end of the business day
occurring nine (9) years thereafter. 
 2. Section 14 of the Agreement is hereby amended to add
the following: 
 (e) Three (3) Month Notice. Either party may terminate this Agreement at any
time upon three (3) months’ prior written notice to the other party. 
 3. Section 29 of
the Agreement is hereby amended to replace the notice information pertaining to Fisher Thurber LLP with the following: 
 K&L Gates LLP 
 3580 Carmel Mountain Road, Suite 200

 San Diego, CA 92130 
 Attn: David A. Fisher, Esq. 
 4. Notwithstanding the provisions of
Section 38 of the Agreement, NSA hereby acknowledges and agrees that Seller may file this Amendment with the United States Securities and Exchange Commission (SEC) and describe the terms of this Amendment in Seller’s filings with
the SEC as required by applicable law and this shall constitute NSA’s consent thereto. 
 5. Except as set
forth herein, all other terms and conditions of the Agreement shall remain in full force and effect. 
 6. This
Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, and such counterparts together shall constitute one instrument. Delivery by facsimile or other electronic means of an
executed counterpart hereof shall have the same force and effect as delivery of an originally executed counterpart hereof. 

[Signatures on following page.] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the Effective Date.

  

			
	NAI
	
	Natural Alternatives International, Inc.,
a Delaware corporation
	
	 /s/    Mark A.
LeDoux        

	Mark A. LeDoux, Chief Executive Officer
	
	NSA
	
	NSA, Inc.,
a Tennessee corporation
		
	By:	 	 /s/ G.O. Giles

	Printed Name:	 	 G.O. Giles

	Title:	 	 VP

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]